Related references
Note: Only part of the references are listed.Population-Based Penetrance of Deleterious Clinical Variants
Iain S. Forrest et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Stem Cell Theory of Cancer: Rude Awakening or Bad Dream from Cancer Dormancy?
Shi-Ming Tu et al.
CANCERS (2022)
HALF OF CANCER STUDIES FAIL HIGH-PROFILE REPLICATION TEST
Asher Mullard
NATURE (2021)
Curing Cancer: Lessons from a Prototype
Shi-Ming Tu et al.
CANCERS (2021)
Stem Cell Theory of Cancer: Origin of Tumor Heterogeneity and Plasticity
Shi-Ming Tu et al.
CANCERS (2021)
Stem Cell Theory of Cancer: Implications of a Viral Etiology in Certain Malignancies
Shi-Ming Tu
CANCERS (2021)
Degree and site of chromosomal instability define its oncogenic potential
Wilma H. M. Hoevenaar et al.
NATURE COMMUNICATIONS (2020)
Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor
Eric C. Umbreit et al.
CANCERS (2020)
Estimation of clinical trial success rates and related parameters
Chi Heem Wong et al.
BIOSTATISTICS (2019)
Improving the odds of drug development success through human genomics: modelling study
Aroon D. Hingorani et al.
SCIENTIFIC REPORTS (2019)
Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens
Eric A. Severson et al.
BLOOD (2018)
How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation
John P. A. Ioannidis et al.
NATURE BIOMEDICAL ENGINEERING (2018)
Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review
David B. Fogel
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS (2018)
Mismatch Repair Deficiency, Microsatellite Instability, and Survival An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial
Elizabeth C. Smyth et al.
JAMA ONCOLOGY (2017)
Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation
Monika Brueggemann et al.
BLOOD ADVANCES (2017)
Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer
Shi-Ming Tu et al.
CANCER (2016)
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Luca Gianni et al.
LANCET ONCOLOGY (2016)
IS THERE A REPRODUCIBILITY CRISIS?
Monya Baker
NATURE (2016)
Autism Linked to Increased Oncogene Mutations but Decreased Cancer Rate
Benjamin W. Darbro et al.
PLOS ONE (2016)
The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease
Tamina Seeger-Nukpezah et al.
NATURE REVIEWS NEPHROLOGY (2015)
High burden and pervasive positive selection of somatic mutations in normal human skin
Inigo Martincorena et al.
SCIENCE (2015)
IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas
Heather E. Leeper et al.
ONCOTARGET (2015)
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial
Sung Hoon Noh et al.
LANCET ONCOLOGY (2014)
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
T. Haferlach et al.
LEUKEMIA (2014)
The scientific method: pillar and pitfall of cancer research
Shi-Ming Tu et al.
CANCER MEDICINE (2014)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
Identification of PPAP2B as a novel recurrent translocation partner gene of HMGA2 in lipomas
Laurence Bianchini et al.
GENES CHROMOSOMES & CANCER (2013)
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing
Dan R. Robinson et al.
NATURE GENETICS (2013)
Raise standards for preclinical cancer research
C. Glenn Begley et al.
NATURE (2012)
Clonal Architecture of Secondary Acute Myeloid Leukemia
Matthew J. Walter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Believe it or not: how much can we rely on published data on potential drug targets?
Florian Prinz et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Daniel J. Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Why most published research findings are false
JPA Ioannidis
PLOS MEDICINE (2005)